drugset / Trial / NCT06400056
Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis
NaSingle-groupOpen-labelDiagnostic
Summary
AIM OF WORK : 1. Detect the most common fungal strains that cause tinea capitis 2. Detect Different effectiveness of terbinafine in different cases 3. Detect the resistant strains. 4. Detect the mycological and the clinical cure rates upon using systemic terbinafine in treatment of tinea capitis
Timeline
- Start
- 2024-05
- Primary completion
- 2025-04
- Completion
- 2025-05
Publications
- Background Appelt L, Nenoff P, Uhrlass S, Kruger C, Kuhn P, Eichhorn K, Buder S, Beissert S, Abraham S, Aschoff R, Bauer A. [Terbinafine-resistant dermatophytoses and onychomycosis due to Trichophyton rubrum]. Hautarzt. 2021 Oct;72(10):868-877. doi: 10.1007/s00105-021-04879-1. Epub 2021 Aug 30. German.
- Background Hawks MK, Rupert JP, Svarverud JE. Terbinafine for Onychomycosis. Am Fam Physician. 2018 Aug 1;98(3):Online. No abstract available.
- Background Lian LD, Shi LY, Zhu J, Liu R, Shi L, Ren A, Yu HS, Zhao MW. GlSwi6 Positively Regulates Cellulase and Xylanase Activities through Intracellular Ca2+ Signaling in Ganoderma lucidum. J Fungi (Basel). 2022 Feb 14;8(2):187. doi: 10.3390/jof8020187.
- Results Moreno-Sabater A, Normand AC, Bidaud AL, Cremer G, Foulet F, Brun S, Bonnal C, Ait-Ammar N, Jabet A, Ayachi A, Piarroux R, Botterel F, Houze S, Desoubeaux G, Hennequin C, Dannaoui E. Terbinafine Resistance in Dermatophytes: A French Multicenter Prospective Study. J Fungi (Basel). 2022 Feb 23;8(3):220. doi: 10.3390/jof8030220.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Terbinafine | Small molecule | 125 mg | Oral |
| Subject | Terbinafine | Small molecule | 187.5 mg | Oral |
| Subject | Terbinafine | Small molecule | 250 mg | Oral |